BFA
NERV icon

Brendel Financial Advisors’s Minerva Neurosciences NERV Stock Holding History

Brendel Financial Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,799
Closed -$252K – 111
2026
Q1 		$252K Buy
+41,799
New +$240K 0.12% 82

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brendel Financial Advisors's NERV Position: Q2 2026 in Review

Brendel Financial Advisors sold out of Minerva Neurosciences (NERV) in Q2 2026, closing a stake of 41,799 shares — an estimated $252K sold.

Brendel Financial Advisors first reported a position in NERV in Q1 2026 and held it in 1 quarter. The position peaked at $252K in Q1 2026. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • Brendel Financial Advisors reported no remaining Minerva Neurosciences position as of Q2 2026 after selling out during the quarter.
  • Brendel Financial Advisors sold 41,799 Minerva Neurosciences shares in Q2 2026, an estimated $252K.
  • Brendel Financial Advisors first reported a position in Minerva Neurosciences in Q1 2026 and held it in 1 quarter.
  • Brendel Financial Advisors's Minerva Neurosciences position peaked at $252K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on Brendel Financial Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.